Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Input metadata referenced "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter and six months ended June 30, 2001.
Status: Development stage enterprise focused on pulmonary drug delivery technologies (Premaire and Tempo systems). The company has generated minimal operating revenue and sustained significant net operating losses since inception in 1986.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $874,095 | $245,675 |
| Net Loss | $(3,859,820) | $(2,840,900) |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.10) |
| Cash and Cash Equivalents (End of Period) | $1,463,968 | $1,846,056 |
| Net Cash Used in Operating Activities | $(2,810,103) | $(3,307,833) |
| Total Assets | $3,502,290 | $5,450,657 (Dec 31, 2000) |
| Total Liabilities | $6,327,105 | $5,864,377 (Dec 31, 2000) |
| Convertible Promissory Note | $2,000,000 | $2,000,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased to $874,095 for the six months ended June 30, 2001, compared to $245,675 in the prior year period. This was driven primarily by contract research revenue ($869,095 vs. $245,675) related to a collaborative agreement with Zambon Group SpA for Premaire device development.
- Expense Increases: Research and development expenses rose to $2,980,135 (from $1,784,778) due to higher costs for Premaire device testing, RSD unit-dose product development, and Tempo Inhaler design. General and administrative expenses increased to $1,877,800 (from $1,386,145) due to higher consulting and legal fees.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $1.58 million to $1.46 million, reflecting cash disbursements for operating activities, partially offset by a $1.0 million milestone advance from Zambon and $1.0 million from Series E preferred stock issuance.
- Accumulated Deficit: The accumulated deficit during the development stage grew to $(85.8) million from $(81.0) million at year-end 2000.
Guidance, Outlook, and Risks
- Capital Requirements: The company requires substantial additional capital to fund ongoing R&D and clinical testing. It does not expect to generate significant cash flows from operations for at least the next few years.
- Recent Financing: On August 14, 2001 (subsequent to period end), the company entered into a Note Purchase Agreement with Elan Pharma International Ltd. for a $2 million loan, with an option for an additional $2 million. The note bears 10% interest compounded semi-annually.
- Collaborations: Key alliances include Zambon (respiratory products via Premaire) and Elan (systemic products via Tempo/Premaire and a joint venture for inhaled steroids). Future revenues depend on the success of these collaborations and clinical trials.
- Risks: Significant risks include the inability to secure additional financing, failure of clinical trials, regulatory delays, and potential dilution from convertible securities. The company faces the risk of defaulting on licensing agreements if milestones are not met.
Investor Verification Checklist
- Verify the status of the $2.0 million milestone advance from Zambon and the conditions required to recognize it as revenue versus repayment obligations.
- Confirm the terms and funding status of the subsequent $4 million credit facility with Elan Pharma International Ltd.
- Assess the progress of Phase III clinical trials for Premaire-albuterol and the development of the Tempo Inhaler.
- Review the company's cash burn rate against current cash reserves ($1.46 million) to estimate the runway before additional financing is required.
- Examine the potential dilution impact of outstanding convertible preferred stock (Series C, D, E, F) and warrants.